Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

3.680 -0.050 (-1.34%)

Delayed Quote Updated: 3:28 PM EDT, Oct 14, 2026 Add to My Watchlist

Price and Volume

Volume	955,984
Open	3.730
Bid (Size)	3.680 (200)
Ask (Size)	3.690 (1,200)
Prev. Close	3.730
Today's Range	3.590 - 3.810
52wk Range	3.670 - 8.740
Shares Outstanding	14,508,063
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Kaplan Fox Alerts Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Seek Leadership in a Securities Fraud Lawsuit by November 2, 2026

Today 7:20 EDT

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

October 13, 2026

A securities class action contends Unicycive Therapeutics promised shareholders an FDA decision on June 29, 2026 and a commercial launch of oxylanthanum carbonate "later this year," while allegedly...

From SueWallSt

Via GlobeNewswire

Performance

52-Week Range 57.9% below 52-week high

3.680

3.6752W Low 8.7452W High

1 Week 12.8% below 1-week high

3.671W Low 4.221W High

Unicycive Therapeutics, Inc. - Common Stock (UNCY) traded between $3.67 and $8.74 over the past 52 weeks and last traded at $3.68, 57.9% below its 52-week high. Over the past week it ranged between $3.67 and $4.22.

Past 12 Months

-12.0%

-28.5%

-29.5%

-47.0%

-36.6%

-18.0%

1W -$0.50

1M -$1.47

3M -$1.54

6M -$3.26

YTD -$2.12

1Y -$0.81

UNCY was -18.0% over the past year, -47.0% over six months, -36.6% year to date, -12.0% in the last week.

12 Months vs Market

UNCY

-18.0%

DIA

+11.7%

SPY

+15.9%

QQQ

+21.1%

IWM

+10.9%

Over the past 12 months UNCY returned -18.0% versus DIA (Dow) +11.7%, SPY (S&P 500) +15.9%, QQQ (Nasdaq 100) +21.1% and IWM (Russell 2000) +10.9%.

Volume & Liquidity 1.14× 3-mo avg

Today 955,984 3-mo avg 841.2K

1.0M

947.8K

841.2K

1.1M

YTD

927.8K

815.5K

UNCY most recently traded 955,984 shares against a 3-month average daily volume of 841.2K.

More News

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

October 12, 2026

From Levi & Korsinsky, LLP

Via GlobeNewswire

Kaplan Fox & Kilsheimer LLP Alerts Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to the Lead Plaintiff Deadline on November 2, 2026

October 12, 2026

Via NewMediaWire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 11, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

October 09, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 08, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Reminds Unicycive Therapeutics, Inc. Investors with Large Losses to Contact the Firm Seeking Lead Plaintiff Role

October 08, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 07, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

UNCY Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Securities Class Action Against Unicycive Therapeutics, Inc.

October 05, 2026

Via Newsfile

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY

October 02, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

Kaplan Fox Class Action Reminder: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Lead Plaintiff Deadline is November 2, 2026

October 02, 2026

Via NewMediaWire

Unicycive Therapeutics Appoints Meredith Manning to Board of Directors

October 01, 2026

Via B2i Digital

Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit Against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is November 2, 2026

September 30, 2026

Via NewMediaWire

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

September 29, 2026

Via B2i Digital

Kaplan Fox Deadline Alert: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors Have Until November 2, 2026 to Seek a Lead Plaintiff Role

September 28, 2026

Via NewMediaWire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 25, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026

September 24, 2026

Via NewMediaWire

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026

September 22, 2026

Via NewMediaWire

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

September 22, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

September 18, 2026

From Robbins LLP

Via Business Wire

Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm Before Lead Plaintiff Deadline on November 2, 2026

September 18, 2026

Via NewMediaWire

Kaplan Fox Reminds Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to a Securities Class Action Deadline - Contact the Firm Before November 2, 2026

September 16, 2026

Via NewMediaWire

Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies

September 15, 2026

Via Newsfile

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

September 15, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

Frequently Asked Questions

Is Unicycive Therapeutics, Inc. - Common Stock publicly traded?

Yes, Unicycive Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Unicycive Therapeutics, Inc. - Common Stock trade on?

Unicycive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Unicycive Therapeutics, Inc. - Common Stock?

The ticker symbol for Unicycive Therapeutics, Inc. - Common Stock is UNCY on the Nasdaq Stock Market

What is the current price of Unicycive Therapeutics, Inc. - Common Stock?

The current price of Unicycive Therapeutics, Inc. - Common Stock is 3.680

When was Unicycive Therapeutics, Inc. - Common Stock last traded?

The last trade of Unicycive Therapeutics, Inc. - Common Stock was at 10/14/26 03:28 PM ET

What is the market capitalization of Unicycive Therapeutics, Inc. - Common Stock?

The market capitalization of Unicycive Therapeutics, Inc. - Common Stock is 53.39M

How many shares of Unicycive Therapeutics, Inc. - Common Stock are outstanding?

Unicycive Therapeutics, Inc. - Common Stock has 53M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.